This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Immunization  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;293:2992.

	Since this article does not have an abstract, we have provided the first 118 words of the full text and any section headings.

The first combination booster vaccine against pertussis, tetanus, and diphtheria for adolescents has been approved by the Food and Drug Administration. It will be marketed as Boostrix by GlaxoSmithKline Inc (Brentford, Middlesex, England) and indicated for use as a single booster dose to adolescents aged 10 to 18 years.

Although combination booster vaccines exist against tetanus and diphtheria, this is the first to include pertussis, a highly communicable disease that can be particularly serious for infants. The disease is usually less severe in adolescents, but they may transmit it to susceptible infants and other family members. In the last 20 years, rates of pertussis infection have been increasing.

More information is available at http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01354.html.

RELATED ARTICLE

Combined Tetanus, Diphtheria, and 5-Component Pertussis Vaccine for Use in Adolescents and Adults
Michael E. Pichichero, Margaret B. Rennels, Kathryn M. Edwards, Mark M. Blatter, Gary S. Marshall, Monica Bologa, Elaine Wang, and Elaine Mills
JAMA. 2005;293(24):3003-3011.
ABSTRACT | FULL TEXT